Refine your search
Collections
Co-Authors
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Mundaganur, Y. D.
- Studies on Nicotinic Acetylcholine Receptor (nAChR) and Acetyl Cholinesterase (AchE) Inhibitors and their Similar Structure for Alzheimer's Disease Using Hex
Abstract Views :226 |
PDF Views:0
Authors
Affiliations
1 Department of Zoology, PVP College, Kavathe Mahankal, Sangli, Mahrashtra 416 416, IN
2 Department of Zoology, Willingdon College, Sangli, Mahrashtra 416 416, IN
3 Department of Zoology, Miraj College, Miraj, Sangli Mahrashtra 416 416, IN
1 Department of Zoology, PVP College, Kavathe Mahankal, Sangli, Mahrashtra 416 416, IN
2 Department of Zoology, Willingdon College, Sangli, Mahrashtra 416 416, IN
3 Department of Zoology, Miraj College, Miraj, Sangli Mahrashtra 416 416, IN
Source
Indian Journal of Public Health Research & Development, Vol 3, No 1 (2012), Pagination: 58-63Abstract
Alzheimer's disease (AD) is the most common cause of dementia among older people, but it is not a normal part of ageing. It is established that a definite relationship between AD and Acetylcholinesterase (AChE) and nicotinic acetylcholine Receptor (nAChR). Acetylcholinesterase inhibitors are employed to reduce the rate at which acetylcholine (ACh) is broken down, thereby increasing the concentration of ACh in the brain and combating the loss of ACh caused by the death of cholinergic neurons. There are many drugs available to counter act the complications of AD. This paper aims to find out the difference between the available drugs and their similar structures to combat the modification nAChR and AchE by docking studies using Hex so as to pin point the best one among the various drugs and their similar structure for better treatment of AD. We observed that similar structure of Rivastigmine. (Bambuterol, Estramustine); Donepezil (Tetrabenazine, Benzquinamide) and Galantamine (Marinol and Deserpidine) are better on the ground better docking result. We studied 14 drugs and similar structures of some of the drugs by Hex docking method. The result showed that all these drugs are not docked well with nAChR having low negative energy. But the docking between AchE and all the drugs selected shows better docking with high negative energy but the similar structure of some of the drugs (Rivastigmine, Donepezil and Galantamine) are better than the mother drugs. Thus we conclude that an immediate drug development research project is needed to produce new generation drugs for AD at the genetic level with caution should be taken to diet factors in the proper age groups to prevent the onset of the disease in the bud condition.Keywords
Alzheimer’s Disease, Nicotinic Acetylcholine Receptor, Acetylcholinesterase, Drugbank, Drugs for AD
References
- Ballard, C., Hanney, M.L., Theodoulou, M., Douglas, S., McShane, R., Kossakowski, K., Gill, R., Juszczak, E., Yu L-M. and Jacoby, R. (2009). The dementia antipsychotic withdrawal trial (DARTAD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurology. 8 (2): 151.
- Birks, J. (2006). Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. (1): CD005593
- Birks, J. and Harvey, R.J. (2006). Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. (1): CD001190
- Brookmeyer, R., Gray, S. and Kawas, C. (1998). Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 88 (9): 1337–1342.
- Brookmeyer, R., Johnson, E., Ziegler,G. K. and Arrighi, H.M. (2007). Forecasting the global burden of Alzheimer’s disease. Alzheimer’s and Dementia. 3 (3): 186–191.
- Colquhoun, D. and Sivilotti, L.G. (2004). Functionand structure in glycine receptors and some of their relatives. Trends Neurosci. 2 (6): 337-344.
- Geula, C.and Mesulam, M.M. (1995). Cholinesterases and the pathology of Alzheimer disease. Alzheimer Dis Assoc Disord. 9 (2): 23–28.
- Greenblatt, H.M., Kryger, G., Lewis, T., Silman, I.and Sussman, J.L.(1999). Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett. 463(3):321-326.
- Imming, P., Sinning, C.and Meyer, A.(2006). Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. (10):821-34.
- Lipton, S.A. (2006). Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov. 5 (2): 160–170.
- Miller, E.R. 3rd, Pastor,B.R., Dalal, D., Riemersma, R.A., Appel, L.J.and Guallar, E. (2005). Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 142(1):37-46.
- Nashmi, R., Dickinson, M.E., McKinney, S., Jareb, M., Labarca, C., Fraser, S.E.and Lester, H.A. (2003). Assembly of alpha4beta2 nicotinic acetylcholine receptors assessed with functional fluorescently labeled subunits: Effects of localization, trafficking, and nicotine-induced upregulation in clonal mammalian cells and in cultured midbrain neurons. Journal of Neuroscience. 23: 11554-11567.
- Pettit, D. L., Shao, Z. and. Yakel, J. L (2001). -Amyloid1-42 Peptide Directly Modulates Nicotinic Receptors in the Rat Hippocampal Slice. The Journal of Neuroscience, 21:RC120:1-5.
- Purves, D., George J. A., David, F., William, C. H., Anthony,S.L., James, O. M. and Leonard E. W. (2008). Neuroscience. 4th ed. Sinauer Associates. pp. 121–122.
- Raina, P., Santaguida, P.and Ismaila, A. (2008). Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Annals of Internal Medicine. 148 (5): 379–397.
- Raschetti, R., Albanese, E., Vanacore, N.and Maggini, M. (2007). Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med. 4 (11): 338.
- Ritchie, D.W. (2003). Evaluation of Protein Docking Predictions Using Hex 3.1 in CAPRI Rounds 1 and 2, PROTEINS: Struct. Funct. Genet. 52, 98-106.
- Ritchie, D.W. and Kemp, G.J.L.(2000). Protein Docking Using Spherical Polar Fourier Correlations, PROTEINS: Struct. Funct. Genet. 39: 178-194.
- Rosler, M., Anand, R., Cicin, S.A., Gauthier, S., Agid, Y., Dal, B.P., Stahelin, H.B., Hartman, R.and Gharabawi, M. (1999). Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ. 318(7184):633- 638.
- Sastre, A .A., McShane, R.and Sherriff, F. (2004). Memantine for dementia. Cochrane Database Syst Rev. (4): CD003154
- Sink, K.M., Holden, K.F.and Yaffe, K. (2005). Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA .293 (5): 596–608.
- Small, D.H. and Fodero, L.R. (2002). Cholinergic regulation of synaptic plasticity as a therapeutic target in Alzheimer’s disease. Journal of Alzheimer’s disease : JAD 4(5):349-55.
- Stahl, S.M. (2000). The new cholinesterase inhibitors for Alzheimer’s disease, Part 2: illustrating their mechanisms of action. J Clin Psychiatry. 61 (11): 813–814.
- Vellas, B., Coley, N.and Andrieu, S.(2008). Disease modifying trials in Alzheimer’s:perspectives for the future disease. Alzheimer’s Dis. 15: 289-301.
- Yesavage, J.A., Mumenthaler, M.S., Taylor, J.L., Friedman, L., O’Hara, R., Sheikh, J., Tinklenberg, J. and Whitehouse, P.J (2002). Donepezil and flight simulator performance: effects on retention of complex skills. Neurology.59 (1):123-125.